LYON, France, June 26 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and provider of ESWL devices for the treatment or urinary stones today announces exclusive distribution of the LMA Urology Suisse S.A. StoneBreaker system in the Malaysia and Korea domestic markets. The Agreement with LMA also grants EDAP worldwide exclusive distribution of the StoneBreaker when bundled with EDAP's existing range of products. This adds to the company's successful March 2007 launch as the exclusive StoneBreaker distributor in LMA's French territory.

The LMA Stonebreaker^™ is a portable intra-corporeal contact lithotripter which fragments stones in the urinary tract. This handheld system complements extracorporeal lithotripsy procedures performed with ESWL devices. The system, manufactured in Switzerland, received the CE mark in June 2006 and is validated by extensive clinical trials confirming the effectiveness of this cynetic intracorporeal lithotripsy technique.

Marc Oczachowski, Chief Executive Officer of EDAP TMS, added, "This agreement offers EDAP a key and unique element of differentiation within the current mature and very competitive lithotripsy market. We are confident that the StoneBreaker combined with our range of extracorporeal lithotripters will strongly support our ESWL sales. This exclusivity agreement also comes at a proper timing in light of the anticipated launch of our new Sonolith I-sys. This will definitely help support our marketing by promoting all complementary options offered by our new device."

Paul Molloy, President and Managing Director of LMA Urology Suisse S.A., commented, "We are pleased to further cement our relationship with EDAP in Malaysia and Korea, expanding upon our successful collaboration in France. Our technologies are highly synergistic, and the EDAP organization in these countries is well suited to our objective to make the innovative LMA StoneBreaker^™ device available to all of the urology medical community there."

About LMA

LMA designs, develops, markets and distributes medical equipment, principally the LMA laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market. For more information about LMA, please see http://www.lmaurology.com.

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Magnolia Investor Relations at (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com.

To sign up for alerts please visit http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm- HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

CONTACT: EDAP TMS S.A. Magnolia Investor Relations

              Blandine Confort     Matt Kreps
              +33 4 78 26 40 46    972 801 4900

SOURCE EDAP TMS S.A.